Genprex shares surge 25.27% intraday on positive preclinical data for REQORSA and anticipation of upcoming business updates.

Genprex, Inc. (GNPX) surged 25.27% during intraday trading, driven by renewed investor interest in its gene therapy research and positive preclinical data for its lead candidate, REQORSA, highlighted in recent social media discussions. The stock’s sharp rise coincided with heightened attention on X, where users emphasized the potential for upcoming business updates and the low float/high borrow rate profile, suggesting short-term volatility. While congressional purchases and mixed hedge fund activity added incremental support, the primary catalyst was the biotech’s preclinical advancements, which reignited speculative momentum. The social media-driven optimism aligned with institutional positioning shifts, though the magnitude of the intraday move underscores retail and speculative trading dynamics over institutional influence.